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Background: Neo-tAnGo, a National Cancer Research Network (NCRN) multicentre randomised neoadjuvant chemotherapy trial
in early breast cancer, enroled 831 patients in the United Kingdom. We report a central review of post-chemotherapy
histopathology reports on the surgical specimens, to assess the presence and degree of response.
Methods: A central independent two-reader review (EP and HME) of histopathology reports from post-treatment surgical
specimens was performed. The quality and completeness of pathology reporting across all centres was assessed. The reviews
included pathological response to chemotherapy (pathological complete response (pCR); minimal residual disease (MRD); and
lesser degrees of response), laterality, the number of axillary metastases and axillary nodes, and the type of surgery. A consensus
was reached after discussion.
Results: In all, 825 surgical reports from 816 patients were available for review. Out of 4125 data items there were 347 discrepant
results (8.4% of classifications), which involved 281 patients. These involved grading of breast response (169 but only 9 involving
pCR vsMRD); laterality (6); presence of axillary metastasis (35); lymph node counts (108); and type of axillary surgery (29). Excluding
cases with pCR, only 45% of reports included any comment regarding response in the breast and 30% in the axillary lymph nodes.
Conclusion: We found considerable variability in the completeness of reporting of surgical specimens within this national
neoadjuvant breast cancer trial. This highlights the need for consensus guidelines among trial groups on histopathology
reporting, and the participation of histopathologists throughout the development and analysis of neoadjuvant trials.
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Neoadjuvant chemotherapy is being used increasingly in the
management of breast cancer, and has been shown to be as
efficacious as adjuvant therapy (Rastogi et al, 2008). There are
established clinical indications for neoadjuvant treatment such as
locally advanced disease including inflammatory breast cancer
(Dawood et al, 2011), and downstaging of large tumours to allow
breast conserving surgery rather than mastectomy (Bonadonna
et al, 1990; Wolmark et al, 2001). Another benefit of neoadjuvant
therapy is in the context of clinical trials, where it offers a unique
opportunity for the evaluation of treatment response with pCR
acting as a surrogate marker of survival. This allows more rapid
assessment of the efficacy of new chemotherapeutic agents, also
enabling early cessation of ineffective treatments and providing an
opportunity to individualise patient treatment at an early stage. In
addition, tumour samples can be collected before, during and after
treatment enabling translational research to identify markers of
response so target patient populations can be identified (Berruti
et al, 2011).
Clinical trials need to recruit large numbers of patients to
achieve sufficient statistical power to detect a treatment effect. The
most efficient way to do this is via multicentre studies, allowing
suitable subjects to be drawn from a much larger patient
population. One major disadvantage of multicentre trials in the
neoadjuvant setting is that the post-treatment excisions are
reported by a variety of pathology departments, with large
variation in specimen handling protocols and reporting styles. At
present, there are no established national guidelines in the United
Kingdom for the histopathological handling of surgical tissue from
neoadjuvant cases, and the reporting of neoadjuvant chemotherapy
breast specimens. In the literature, there are several different
systems for the histological grading of chemotherapy response
(Marchio and Sapino, 2011). Many of the suggested systems in
common use, rely on a comparison between tumour cellularity of
the pre-treatment core biopsy and the post-treatment resection
specimen (Figure 1), with the grade of response determined by the
reduction in overall cellularity (Chevallier et al, 1993; Sataloff et al,
1995; Smith et al, 2002; Ogston et al, 2003; Pinder et al, 2007). The
MD Anderson group have proposed an alternative system, the
Residual Cancer Burden (RCB), that derives a score based on
tumour bed volume, average tumour cellularity, number of
involved lymph nodes and the size of the largest metastasis
(Symmans et al, 2007). They have shown a relationship between
RCB and survival outcome. The score relies on absolute cellularity
post-treatment, without considering the change from pre-treat-
ment cellularity. Traditional tumour grading systems used in the
adjuvant setting, including the Nottingham Prognostic Index (NPI)
and the TNM system using the prefix ‘y’ to indicate neoadjuvant
treatment, have also been shown to retain their prognostic value
post-chemotherapy (Chollet et al, 2003; Carey et al, 2005).
In the setting of neoadjuvant clinical trials, histopathologists are
a vital part of the trial as thorough specimen handling and accurate
histological reporting is essential to correctly assess the primary
end point (Sahoo and Lester, 2009). In many multicentre
neoadjuvant chemotherapy trials to date, patient outcome is
established by reporting of pathology data from the treating
hospital without any (minimal) guidelines for specimen handling
or centralised review of histopathology reports and/or slides to
ensure validity and reproducibility of results. The Neo-tAnGo trial
was a multicentre phase III randomised study examining the
addition of gemcitabine to a standard neoadjuvant therapy
regimen of epirubicin and cyclophosphamide with paclitaxel. The
primary end point was pCR in both the breast and axilla. A central
review of the post-treatment histopathology reports within the
Neo-tAnGo trial was carried out, not only to assess the presence of
chemotherapy response but also to examine variation in the quality
and completeness of pathology reporting between centres.
MATERIALS AND METHODS
The Neo-tAnGo trial was a multicentre phase III randomised study
of 831 patients from 57 centres examining the addition of
gemcitabine to a standard neoadjuvant therapy regimen of
epirubicin and cyclophosphamide with paclitaxel. The primary
end point is pCR in the breast and axilla. Patient eligibility,
treatment protocols and preliminary results have been described
previously (Earl et al, 2009).
Histopathology reports were requested for all trial patients from
92 centres as per the trial protocol. The reports were received by
the trial co-ordinating centre and were anonymised with respect to
all patient details, with only the neo-tAnGo trial number available
to reviewers. The reports were then independently reviewed by two
study investigators, the study histopathologist (EP) and the chief
investigator of the study, a medical oncologist (HME). A central
pathology review form was completed by each reviewer, collecting
information on the laterality of the surgery; whether or not there
had been a pCR in the breast (yes/no/unknown); the absence of
metastatic disease in the axillary lymph nodes post-treatment
(yes/no/unknown); the nature of axillary lymph node surgery
(pre-treatment sentinel lymph node biopsy (SLN), post-treatment
SLN and/or post-treatment axillary clearance (ALND)) and the
number of lymph nodes sampled and the number of lymph nodes
involved for each type of surgery. In cases where there had not
been a pCR in the breast, the reports were further subcategorised as
minimal residual disease (490% response), chemotherapy
response present, no chemotherapy response and no comment
regarding chemotherapy response. A subset of cases was also
independently reviewed by a third party (KW). Following collation
Figure 1. (A) Pre-treatment core biopsy and (B) post-chemotherapy excision specimen showing good response to neoadjuvant chemotherapy with
a marked reduction in cellularity following treatment.
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of the review findings, cases in which there was disagreement
between reviewers were discussed jointly and a consensus was
reached. Further information was recorded by one of the reviewers
(EP) regarding the number of histology blocks taken in cases with a
pCR, whether there was formal grading of chemotherapy response
and what system was used, and whether or not the reports
commented on the presence or absence of changes suggesting
response to chemotherapy in the axillary lymph nodes (Figure 2).
RESULTS
Histopathology reports were received for review from 816 of 831
patients. Ten patients had bilateral disease, making a total of 826
breast reports reviewed. One patient refused surgery and only had
a core biopsy after treatment, this case is excluded from further
analysis although of note it was classified as pCR by one reviewer
and breast response unknown by the other.
The review of the reports looked at five main pieces of data;
laterality, breast response, the presence of axillary metastases,
axillary node number and type of axillary node surgery. For the 825
breast operations this gives a total of 4125 data points. There were
347 discrepancies between the two reviewers involving 281
subjects, representing 8.4% of classifications. Forty-eight subjects
had two discrepancies, eight subjects had three discrepancies and
one subject with bilateral disease had four discrepancies.
The discrepancies were in the following areas; 6 – laterality, 169
– grading of breast response, 35 – presence of axillary metastasis,
108 – lymph node counts and 29 – type of axillary lymph node
surgery.
Interpretation of response in the breast. The 169 discrepancies
regarding grading of response in the breast are detailed in Table 1.
Nine were pCR vs MRD, and in four of these cases there was no
axillary metastasis so this potentially altered the primary end point
for these subjects. The commonest discrepancies were chemother-
apy response vs no comment (82) and MRD vs chemotherapy
response (45). The oncologist and chief investigator (HME) tended
to interpret the pathology report as indicating the presence of
chemotherapy response more frequently than the pathologist
(Figure 3). This was because the oncologist interpreted any
mention of necrosis or fibrosis as indicating chemotherapy
response, whereas the pathologist required an explicit statement
within the report as to the presence of chemotherapy response,
since both necrosis and fibrosis are commonly seen in breast
cancer histopathology in the absence of chemotherapy.
Interpretation of axillary lymph nodes. Of the 35 disagreements
regarding the presence of axillary metastasis, 7 were in patients
who had a pre-treatment SLN with no further axillary surgery; one
of the reviewers called these negative while the other called them
‘not known’. Midway through the review it was agreed to call these
cases negative for post-treatment metastasis. A further nine
discrepancies were errors secondary to the wording of the form;
‘Yes’ indicating an ‘absence of metastasis’. The remaining cases
relate to differences in interpretation of the pathology findings
such as isolated tumour cells (ITC’s) (5), cells identified by
immunohistochemistry only (3), deposits in axillary nodal fat (2),
scarring in lymph nodes (1) and involvement of an intramammary
lymph node (1).
There was disagreement in the number of lymph nodes,
including the number of nodes sampled and/or the number of
nodes involved, in 108 cases. In 52 cases, the source of the
disagreement was not recorded. For the remaining cases, reasons
for disagreement included interpretation of ITC’s (13), errors/
inconsistencies in the pathology report, for example, different
Table 1. Reviewer discrepancies with chemotherapy response status
Change to final
response
status
Reviewer 1 agrees
with final response
status
Reviewer 2 agrees
with final response
status
MRD to pCR 1 (1%) 1 (1%)
pCR to MRD 3 (2%) 4 (2%)
CRNG to MRD 6 (4%) 1 (1%)
MRD to CRNG 1 (1%) 37 (22%)
CRNG to NC 9 (5%) 47 (28%)
NC to CRNG 8 (5%) 18 (11%)
NR to CRNG 1 (1%) 3 (2%)
MRD to NC 1 (1%) 10 (6%)
NC to MRD 3 (2%)
MRD to NR 1 (1%)
NC to NR 1 (1%)
NR to NC 9 (5%)
0
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Figure 3. Comparison of scores of chemotherapy response from
reviewer 1 and reviewer 2 with final score. (pCR – pathological
complete response: MRD – minimal residual disease: CRNG –
chemotherapy response non-gradable: NR – no response: NC – no
comment in report on chemotherapy response).
Figure 2. Lymph node showing metastasis with response to treatment
with a focal area of fibrosis containing haemosiderin laden
macrophages.
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numbers recorded in the microscopic findings and conclusion (13),
missed pre-treatment SLNs (8), missed delayed ALND (5), nodes
positive on IHC only (4), classification of internal mammary and
intramammary lymph nodes (3), the presence of multiple speci-
mens (2) and missed axillary tail lymph nodes in mastectomy
specimens (2). In 29 cases, the discrepancy was in the type of
lymph node surgery; 18 SLN vs ALND, 6 the classification of
axillary sampling specimens and 5 pre- vs post-treatment.
Final consensus classification of chemotherapy response. The
final classification for the 825 cases based on the combined review
of the breast reports was pCR in 188, MRD in 85, chemotherapy
response present in 228, no response in 17 and no comment
regarding response in 307 (Table 2). In cases classified as MRD, the
presence of chemotherapy response had been mentioned in 45
reports but only 13 of these reports included formal grading of
response, with one stating ‘MRD’, seven giving a percentage
response 490% and five giving a Miller–Payne score of 4.
The remaining cases were classified as MRD by the reviewers on
the basis of invasive tumour size o5mm, the presence of DCIS
with microinvasion, scattered single cells detectable by immuno-
histochemistry or the presence of lymphovascular space invasion
only. Overall, only 287 of the 637 (45%) reports from patients who
did not achieve pCR contained a specific reference to the presence
of chemotherapy effect. Of these, only 55 (8.6%) gave some sort of
formal grading of response, with 20 using the Miller–Payne
grading score, 20 giving a percentage change in cellularity, one
stating that there was ‘MRD’ and 14 stating that there was ‘no
response’.
Nature of axillary surgery and assessment of axillary response.
The lymph node procedures performed are summarised in Table 3.
In all, 154 out of 816 (19%) patients underwent a SLNB, 60 out of
154 (39%) before commencement of chemotherapy and 94 out of
154 (61%) after completion of chemotherapy at the time of their
breast surgery. Of the 60 patients who had a pre-treatment SLNB,
26 went on to have a post-chemotherapy ALND; 3 of these patients
had a negative pre-treatment SLNB. Forty patients who had a post-
treatment SLNB went on to an ALND, 29 as an immediate and 11
as a delayed procedure. Thirteen patients with a positive post-
treatment SLNB had no further surgery; one had ITC’s, two had
micromets, two had metastases elsewhere and for the remaining 8
the data are missing. In all, 668 patients (81%) had an ALND as
their only axillary surgery, and 3 patients underwent no axillary
surgery.
In total, 788 patients had some form of post-chemotherapy
lymph node surgery, and 433 (55%) of these had axillary
metastases. In all, 44 of these patients had a pCR in the breast,
and the axillary disease was the only residual tumour present. It
was decided to call the presence of any metastatic disease in the
axilla positive including isolated tumour cells (ITC’s). In all, 36
patients had documented ITC’s post-chemotherapy; in 20 (55%)
reports these were regarded as positive, and in the remaining 16
(45%) reports the nodes were called negative. In four of these
patients ITC’s represented the only nodal disease so the
interpretation of ITC’s changed the nodal status; however, all of
these patients had residual disease in the breast so it did not alter
the overall response status. When trying to determine response in
the lymph nodes, only 238 out of 788 (30%) reports made a specific
comment regarding the presence or absence of chemotherapy
related changes; 125 out of 355 (35%) reports with negative lymph
nodes and 115 out of 433 (27%) reports with positive lymph nodes.
Review of specimen handling. To look at the degree of specimen
sampling in patients with a pCR, the pathology reports were
examined to determine the number of blocks taken to search for
residual disease. For 91 out of 188 cases (48%), the block
description did not form part of the pathology report and it was
impossible to determine the number of blocks taken. In the
remaining 98 cases, the number of blocks taken ranged from 5 to
81, with large blocks regarded as equivalent to 4 small blocks.
Twelve cases had less than 10 blocks, 55 cases had 10–19 blocks, 14
cases had 20–29 blocks and for 16 cases 30 or more blocks were
taken.
DISCUSSION
Neoadjuvant chemotherapy is being increasingly accepted as
firstline treatment for primary breast cancer. It is the preferred
treatment option for locally advanced disease particularly inflam-
matory breast cancer, and can be used in an attempt to downstage
large tumours to allow breast conservation surgery. There is also
emerging evidence that it may be beneficial in certain patient
subgroups, such as women under the age of 50 and women with
ER-negative disease (Rastogi et al, 2008; Berruti et al, 2011). The
assessment of tumour response to chemotherapy provides
important prognostic information for ongoing patient manage-
ment, with pCR showing a strong association with improved DFS
and OS. However, the degree of response remains a predictor of
treatment efficacy even in the absence of pCR, and this may be
particularly relevant in tumour subtypes where pCR is uncommon
such as ER positive/luminal cancers. In patients that respond
poorly or progress on neoadjuvant therapy, outcomes are poor and
it provides the opportunity to change chemotherapy regimens or
trial novel agents. However, results from the former approach have
been disappointing thus far (von Minckwitz et al, 2008) and at
present, although information about the amount of residual
tumour is prognostically useful, it does not typically alter patient
management.
The other advantage of neoadjuvant therapy is in the setting of
clinical trials such as the neo-tAnGo trial. pCR represents a
surrogate end point for survival in this context, enabling more
Table 2. Classification of chemotherapy response within the breast
Final grading of breast response
pCR 188 (23%)
MRD 85 (10%)
Chemotherapy response present 228 (28%)
No response 17 (2%)
No comment re-chemotherapy response 307 (37%)
All non-pCR cases
Formal comment re-chemotherapy response 287 (45%)
No comment re-chemotherapy response 350 (55%)
Table 3. Nature of lymph node surgery and nodal status
Lymph node
surgery
No
metastases
Metastases
present
SLNB – total 154
Pre-chemo 60 37 23
Post-chemo 94 50 44
ALND – total 734 314 420
Only axillary surgery 668 289 379
þ Pre-SLNB 26 16 10
þ Post-SLNB 40 9 31
Comment regarding 125/355 (35%) 115/433 (27%)
Nodal response
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rapid analysis of results and the use of smaller patient cohorts
(Generali et al, 2011). The neoadjuvant setting also provides a
unique opportunity for translational research, with the ability
to collect tumour samples before, during and after treatment to
examine the effects of chemotherapy on tumour biology and
identify novel markers of response.
An example of this approach is measuring Ki67 labelling index
after a short course of neoadjuvant endocrine therapy (Dowsett
et al, 2009). A high Ki67 labelling index 2 weeks after commencing
treatment is associated with poor response to endocrine therapy,
with the option of introducing chemotherapy in these patients.
In the neo-tAnGo trial, pCR was defined as absence of invasive
carcinoma in both the breast and axillary lymph nodes, with residual
DCIS in the breast permitted. This is now the most widely accepted
definition of pCR. Previous studies, such as the NSABP B18 and B27
trials, regarded pCR as absence of residual invasive cancer in the
breast only; residual axillary metastatic disease was accepted (Rastogi
et al, 2008). In these trials, post-operative nodal status was a strong
independent predictor of both DFS and OS. Other studies have also
identified axillary pCR as an important marker of improved
outcome, even in patients who do not achieve pCR in the breast
(Rouzier et al, 2002; Hennessy et al, 2005; Sakakibara et al, 2009).
Interestingly in 44 patients in the neo-tAnGo study there was
residual axillary nodal disease despite a pCR in the breast. This may
represent a true difference in chemosensitivity of metastatic disease vs
the primary tumour, and in some cases there is minimal change in
axillary nodal deposits despite the presence of marked chemotherapy
effect in the primary cancer (EP personal observation). Alternatively,
it may in part represent a sampling issue, with axillary lymph nodes
being entirely embedded compared with more limited sampling of
the primary tumour bed which may be quite extensive or difficult to
localise. The other controversy is whether or not to include residual
DCIS in pCR. Several studies have now shown that the presence of
DCIS does not alter prognosis in patients with complete eradication
of the invasive cancer (Jones et al, 2006; Mazouni et al, 2007). In
addition, excluding cases with DCIS narrows the pCR group and may
confound the results of biomarker studies (Mazouni et al, 2007).
As pCR is the primary end point in neoadjuvant trials, the
histopathologist assumes a pivotal role as thorough specimen
handling and accurate reporting of results is vital to correctly
assigning patient outcome. Histopathologists should be engaged as
key members of the clinical trial team in participating centres, and
criteria for specimen handling and reporting should be included
within the trial design. This central review of pathology reports in a
multicentre trial has revealed huge variation between laboratories.
At present there are no national UK consensus guidelines for
handling and reporting of neoadjuvant breast chemotherapy
specimens, although this will be addressed in the forthcoming
updated edition of the UK guidelines (personal communication,
Professor SE Pinder).
Ideally, while handling a neoadjuvant chemotherapy specimen,
the pathologist should have access to the pre- and post-treatment
imaging findings so they know the number of tumour foci and
their site and size. The sampling of neoadjuvant specimens will be
influenced by whether or not there is a residual macroscopic lesion,
the presence of a clip indicating the tumour bed, and the extent of
disease on imaging pre-treatment. Recommendations in the
literature are often vague, ranging from six or more sections from
a mastectomy specimen including at least one section from the
nipple (Chevallier et al, 1993), ‘multiple’ sections from the biopsy
site and random sections of the nipple and four quadrants (Sataloff
et al, 1995), to a minimum of 10–15 blocks in cases where there is
no palpable tumour (Buzdar, 2007). In the Miller–Payne scoring
system it is recommended at least four sections be taken if there is
macroscopic residual tumour or the whole face of the tumour scar
should be sampled, and a patient can only be regarded as having
had a grade 5 response (pCR) if the previous tumour site is
identified histologically in the form of a fibroelastotic scar (Ogston
et al, 2003). The placement of radio-opaque clips in the tumour
bed prior to commencement of chemotherapy is important for
localisation for breast conserving surgery, and has been shown to
reduce local recurrence rates (Oh et al, 2007). However, even in
patients undergoing mastectomy, the presence of a marker is an
extremely useful aid for the pathologist in accurately localising the
site of the tumour when there has been an excellent response with
no gross residual disease, resulting in more efficient sampling and
reliable determination of the presence of pCR.
In patients who did not achieve pCR in this review, there was a
comment regarding the presence of chemotherapy effect in the
breast in only 45% of cases, with formal grading of response in
o10%. Non-pCR cases include a huge spectrum of tumour
response, from near eradication of disease to a complete absence of
treatment effect. Quantification of residual disease is important, as
in patients who do not achieve a pCR the degree of chemotherapy
response is still a predictor of treatment efficacy. Studies using both
the Miller–Payne scoring system and the Residual Cancer Burden
have shown decreasing tumour cellularity correlates with better
survival outcomes in the absence of pCR (Ogston et al, 2003;
Symmans et al, 2007). Similar outcomes have been shown between
patients with pCR and those with MRD (Penault-Llorca et al,
2008). Reporting on the presence of chemotherapy effect in the
axillary lymph nodes within neo-tAnGo was even worse, with less
than a third of reports commenting on nodal response. This is
particularly important in patients who are node negative
post-chemotherapy, as clinical pre-treatment nodal status is an
important marker of outcome and risk of local recurrence, and the
presence of pre-treatment nodal metastases may be used in clinical
decision making, particularly with regards to adjuvant radio-
therapy (Dawood et al, 2008; Papa et al, 2008). The reasons for the
poor reporting of nodal response are uncertain; some systems for
grading chemotherapy response, such as the original description of
the Miller–Payne system, do not include separate scoring of nodal
response, and there may be a lack of understanding of the clinical
significance of nodal response by pathologists.
The poor reporting of chemotherapy response other than pCR
in this review highlights the need for consensus guidelines for the
handling of neoadjuvant chemotherapy specimens. A formal
grading system needs to be included in reports; however, there
are several systems in the literature each with advantages and
disadvantages (Pinder et al, 2007; Marchio and Sapino, 2011). The
only system used by study centres in the neo-tAnGo trial was the
Miller–Payne system. This is a relatively easy to use system that
divides response into five grades, with grade 1 being no change or
alteration in cell morphology with no reduction in cellularity, grade
2 being up to 30% loss of cellularity, grade 3 30–90% loss of
cellularity, grade 4 490% loss of cellularity and grade 5 being
fibrous stroma with no identifiable tumour cells but DCIS
permitted (pCR) (Ogston et al, 2003). The main disadvantages
are that it grades response in the breast only, and requires
comparison between cellularity in the pre-treatment core biopsy
and the excision specimen. The pre-treatment core biopsy may not
be available if it was performed in another centre, and it must be
assumed cellularity in the core is representative of tumour
cellularity as a whole. Similarly, there is the dilemma of how to
report cases where there has been a marked reduction in the size of
the tumour but the residual tumour remains highly cellular. An
alternative grading system, the Residual Cancer Burden, derives a
score based on tumour bed volume, average tumour cellularity,
number of involved lymph nodes and the size of the largest
metastasis (Symmans et al, 2007). The score relies on absolute
cellularity post-treatment, which has the advantage of not
requiring the pre-treatment core biopsy to grade response.
However, it is relatively labour intensive as cellularity must be
assessed on several slides, and tumour size must be accurately
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measured in two dimensions, which can be difficult
post-chemotherapy when there is no residual macroscopic lesion.
It cannot be applied in patients who had a positive pre-treatment
SLN.
Interestingly, we found a difference in the interpretation of
reports as to presence of chemotherapy response by a specialist
breast histopathologist and an oncologist. The oncologist tended to
regard any mention of fibrosis, necrosis or inflammation as
indicating chemotherapy effect, whereas the histopathologist
required a specific statement in the report that chemotherapy
effect was present. The oncologist involved was also the chief
investigator of the trial, and this may represent a subconscious bias
given the time invested in establishing a multi centre clinical trial
such as neo-tAnGo. Untreated breast cancers can show features
such as fibrosis, inflammation and necrosis. In a central review of
breast cancers in the tAnGo trial, a multicentre clinical trial
looking at the addition of gemcitabine in the adjuvant setting, 8%
of cancers had fibrosis, 22% had necrosis and 44% had a
lymphocytic inflammatory cell infiltrate (EP, unpublished data).
One study found no difference between tumours treated or
untreated by chemotherapy with regards to elastosis, necrosis,
inflammatory infiltrate or infiltration by macrophages, but there
was a significant difference in background breast lobules with
cellular atypia, hyalinisation and stromal fibrosis more common
post-chemotherapy (Aktepe et al, 1996). Hence, oncologists should
look for a specific statement within the pathology report regarding
the presence or absence of chemotherapy response and it’s degree;
if there is no comment regarding chemotherapy effect they should
ask the reporting pathologist to go back and review the case, rather
than interpret features such as necrosis and inflammation as
indicative of response.
Within the neo-tAnGo trial, there was also variation between
centres in the management of the axilla. SLNB was performed in
154 patients, 39% pre-treatment and 61% post-chemotherapy, with
66 patients going on to a post-treatment ALND. This includes
three patients who had a negative SLN pre-chemotherapy, and 29
patients who went on to an immediate ALND after post-treatment
SLN, the majority of whom didn’t have any form of intraoperative
nodal assessment. Hence, the vast majority of patients went
directly to a post-treatment ALND. There is an increasing body of
evidence that SLN is a reliable technique in the neoadjuvant setting
with equivalent results to untreated patients, although there is
some controversy as to the optimum timing of the procedure and
further clinical trials are awaited to address this issue. (Mamounas
et al, 2005; Newman et al, 2007; Hunt et al, 2009; Bear, 2010;
Shimazu and Noguchi, 2011).
After the presence of chemotherapy response, the main source
of disagreement between reviewers was in lymph node numbers.
This was often due to miscounting when there were multiple
lymph node specimens, either within the one procedure or as
separate procedures. The use of proformas with a summary of the
total number of lymph nodes examined makes the report easier to
interpret, although on occasion internal inconsistencies in nodal
numbers were introduced. The other key reason for disagreement
was differences in the interpretation of ITC’s by both reviewers and
reporting pathologists. The significance of ITC’s in the neoadju-
vant setting is controversial. One study showed worse outcome in
patients with residual nodal disease regardless of the size of the
deposit, although the measurements used were o1 cm, 1–10 cm
and 410 cm, which does not allow discrimination between
micrometastases and ITC’s (Hennessy et al, 2005). Other series
show no difference in outcome between patients with axillary pCR
and ITC’s including ITC’s identified by immunohistochemistry
alone (Loya et al, 2009; Sakakibara et al, 2009). The 7th edition of
the AJCC TNM staging system recommends that these patients
should be classified as ypN0(iþ ) as for untreated disease, but
regarded as not having had a pCR (AJCC, 2010).
In summary, this central review of histopathology reports within
a multicentre neoadjuvant clinical trial has revealed wide variation
in the handling and reporting of post-chemotherapy breast cancer
specimens in different centres across the United Kingdom. The
presence of chemotherapy response in the breast and lymph nodes
are important prognostic factors, and were commented on in 45%
and 30% of cases, respectively. This highlights the importance of
national guidelines for the reporting of neoadjuvant chemotherapy
specimens, as well as the need to engage histopathologists as well as
oncologists as key clinicians in neoadjuvant clinical trials.
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